Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone
- 2 April 2003
- journal article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 89 (1) , 180-190
- https://doi.org/10.1002/jcb.10490
Abstract
Parathyroid hormone (PTH) has biphasic effects on bone: continuous treatment is catabolic whereas intermittent treatment is anabolic. The mechanism(s) responsible for these differing effects are still unclear, partly because of the previous non‐availability of a model system in which effects on both formation and resorption indices could be studied concomitantly. In cultured marrow cells from 6‐week old C57BL/6 mice, we demonstrated that 4 days of intermittent PTH treatment increased mRNA for osteoblast differentiation markers (Runx2, alkaline phosphatase (AP), and type I procollagen (COL1A1) whereas continuous treatment resulted in production of large numbers of TRAP‐positive multinucleated osteoclasts. Although IGF‐I mRNA did not increase after intermittent treatment, it was consistently higher than after continuous treatment, and the addition of an anti‐IGF‐I neutralizing antibody prevented the increase in bone formation indices observed with intermittent treatment. By contrast, after continuous treatment, gene expression of RANK ligand (RANKL) was increased and that of osteoprotegerin (OPG) was decreased, resulting in a 25‐fold increase in the RANKL/OPG ratio. In this model system, the data suggest that intermittent PTH treatment enhances osteoblast differentiation through an IGF‐I dependent mechanism and continuous PTH treatment enhances osteoclastogenesis through reciprocal increases in RANKL and decreases in OPG. J. Cell. Biochem. 89: 180–190, 2003.Keywords
This publication has 48 references indexed in Scilit:
- Assessment of Gene Regulation by Bone Morphogenetic Protein 2 in Human Marrow Stromal Cells Using Gene Array TechnologyJournal of Bone and Mineral Research, 2001
- Continuous Parathyroid Hormone and Estrogen Administration Increases Vertebral Cancellous Bone Volume and Cortical Width in the Estrogen-Deficient RatJournal of Bone and Mineral Research, 2001
- The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone ResorptionJournal of Bone and Mineral Research, 2000
- Differentiation of Human Marrow Stromal Precursor Cells: Bone Morphogenetic Protein-2 Increases OSF2/CBFA1, Enhances Osteoblast Commitment, and Inhibits Late Adipocyte MaturationJournal of Bone and Mineral Research, 1999
- Anabolic or Catabolic Responses of MC3T3-E1 Osteoblastic Cells to Parathyroid Hormone Depend on Time and Duration of TreatmentJournal of Bone and Mineral Research, 1999
- Transforming Growth Factor-β1 Increases mRNA Levels of Osteoclastogenesis Inhibitory Factor in Osteoblastic/Stromal Cells and Inhibits the Survival of Murine Osteoclast-like CellsBiochemical and Biophysical Research Communications, 1998
- Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cyclic adenosine monophosphate pathwayEndocrinology, 1996
- Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype.The Journal of cell biology, 1996
- Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosisTrends in Pharmacological Sciences, 1995
- Desensitization of parathyroid hormone receptors on cultured bone cellsJournal of Bone and Mineral Research, 1990